News | December 10, 2025
Lilly to invest $6 billion in Huntsville manufacturing hub
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
The center will offer training to super-specialist doctors and healthcare professionals in various fields
Growing patent filings and tier-2 innovators reflect expanding national research base
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Subscribe To Our Newsletter & Stay Updated
